Atta-Fosu, Thomas http://orcid.org/0000-0001-9259-3592
LaBarbera, Michael
Ghose, Soumya
Schoenhagen, Paul
Saliba, Walid
Tchou, Patrick J.
Lindsay, Bruce D.
Desai, Milind Y.
Kwon, Deborah
Chung, Mina K.
Madabhushi, Anant
Funding for this research was provided by:
National Cancer Institute (R01CA202752-01A1, R01CA208236-01A1, R01 CA216579-01A1, R01 CA220581-01A1, 1U24CA199374-01)
DOD Prostate Cancer Research Program (W81XWH-15-1-0558)
National Heart, Lung, and Blood Institute (R01 HL111314)
National Institutes of Health (UL1-RR024989)
National Cancer Institute (1U01CA239055-01, 1U01CA248226-01, 1U54CA254566-01)
DOD Prostrate Cancer Research Program (W81XWH-20-1-0851)
Article History
Received: 11 May 2020
Accepted: 28 February 2021
First Online: 9 March 2021
Declarations
:
: The study was approved by the Cleveland Clinic Institutional Review Board for retrospective medical records and imaging review and performed in accordance with institutional guidelines.
: Not applicable.
: Dr. Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck. Currently he serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips and Bristol Meyers-Squibb. His technology has been licensed to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc.